Articles related to MEDICARE

New research underscores the dramatic increase in prior authorization for oral oncology drugs under Medicare Part D. Understand the implications for your practice as insurers tighten their grip on treatment decisions.

The HHS has initiated a landmark policy to negotiate drug prices under Medicare Part D. Be prepared for how these changes could affect your patients’ medication affordability starting in 2026.

Explore the complexities and challenges that could arise for oncologists with the potential expansion of blood biopsy insurance coverage through the MCED Screening Coverage Act.

The recent proposal by CMS to cut radiation therapy reimbursement by 2% in 2024 has led to serious concerns among radiation oncology specialists. With cumulative reductions reaching 20% over the past decade, the potential impact on patient access, especially in rural areas, and the perceived devaluation of the field are urgent issues that call for thoughtful consideration and response.

The recent study exploring the Mark Cuban Cost Plus Drug Company’s potential impact on Medicare’s oncology drug spending uncovers significant savings opportunities. Physicians may find interest in this model’s potential to improve access to essential cancer medications through reduced costs, emphasizing a call to examine current overpayment within the Medicare system.

The potential removal of the DIEP flap’s unique medical billing code by CMS could pose significant barriers to this beneficial breast reconstruction option, prompting calls for its preservation to ensure continued access and patient choice. Dive in to explore the implications of this pivotal issue for breast cancer patients and the health care system.